AC Immune reports week-100 safety results from Parkinson’s disease trial
AI Summary- AC Immune reported week-100 Part 1 results from its Phase 2 VacSYn trial of ACI-7104.
- Thirty-four patients were randomized, including 25 receiving ACI-7104 and nine receiving placebo.
- AC Immune is preparing an expanded Part 2 design for FDA review and early-2027 regulatory meetings.